×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANRO – alto neuroscience, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/23
08:33 am
anro
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Medium
Report
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2/17
08:02 am
anro
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
High
Report
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
2/13
08:04 am
anro
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Low
Report
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
2/3
08:54 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
2/3
08:27 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
1/20
09:31 am
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
Medium
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
1/14
07:51 am
anro
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]
Medium
Report
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]
1/14
07:27 am
anro
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Low
Report
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/3
07:16 pm
anro
Form 4 Alto Neuroscience, Inc. For: Mar 01 Filed by: Etkin Amit
Medium
Report
Form 4 Alto Neuroscience, Inc. For: Mar 01 Filed by: Etkin Amit
3/3
07:15 pm
anro
Form 4 Alto Neuroscience, Inc. For: Mar 01 Filed by: Smith Nicholas Conrad
Medium
Report
Form 4 Alto Neuroscience, Inc. For: Mar 01 Filed by: Smith Nicholas Conrad
2/18
04:46 pm
anro
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: ARMISTICE CAPITAL, LLC
2/17
09:53 pm
anro
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: ARMISTICE CAPITAL, LLC
2/17
04:41 pm
anro
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: K2 HealthVentures Equity Trust LLC
Medium
Report
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: K2 HealthVentures Equity Trust LLC
2/17
04:31 pm
anro
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Point72 Asset Management, L.P.
2/17
04:14 pm
anro
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Commodore Capital LP
Medium
Report
Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Commodore Capital LP
2/17
04:06 pm
anro
Form SCHEDULE 13G Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP
Medium
Report
Form SCHEDULE 13G Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: